P7C3 Compounds as Targeted Mitochondrial Therapeutics for Brain Disorders
In brief
P7C3 boosts mitochondrial health and protects brains in animal models of Alzheimer, Parkinson, stroke and trauma
A systematic review found that P7C3 compounds raise NAD+ levels, activate SIRT1/3 pathways, improve mitochondrial quality control and reduce oxidative stress, leading to neuroprotection across preclinical models of Alzheimer disease, Parkinson disease, traumatic brain injury, ischemic stroke, depression and chemotherapy-induced neuropathy. Clinical translation is limited by safety concerns around NAMPT activation and lack of predictive biomarkers, leaving the therapeutic promise untested in humans.
- Journal
- CNS neuroscience & therapeutics (Q1)
- Published
- 1 September 2026
- Study design
- Systematic review of cohort studies
- Evidence level
- Level 2, Moderate (CEBM 2a)
- Authors
- Yajing Chen, Xiaohuan Du, Fang Li, Shuwei Yuan, Wenjing Wang, Zengyan Zhu, et al.
- PMID
- 42698301
- DOI
- 10.1002/cns.71139
Why clinicians should know about it
- Picked for Biochemistry (medical) (paper of the day, 8 September 2026): P7C3 compounds, mitochondrial NAD+ pathway, neuroprotective mechanisms
Abstract
BACKGROUND: P7C3 compounds are aminopropyl carbazole derivatives identified through phenotypic screening for proneurogenic activity. They directly activate nicotinamide phosphoribosyltransferase (NAMPT), the rate-limiting enzyme in the NAD+ salvage pathway. However, a comprehensive synthesis of their mechanisms and therapeutic potential across neurological disorders is currently lacking. METHODS: A systematic literature review was conducted in PubMed, Web of Science, and Scopus to synthesize the discovery trajectory, structure-activity relationships, molecular mechanisms, and preclinical efficacy of P7C3 compounds. The following keyword combinations were used: ("P7C3" OR "P7C3 compound") AND ("NAMPT" OR "NAD+" OR "sirtuin" OR "mitochondria") AND ("neuroprotection" OR "neurodegenerative"). RESULTS: P7C3 elevates intracellular NAD+ levels, engages SIRT1 and SIRT3 deacetylase cascades, enhances mitochondrial quality control and attenuates oxidative stress. This review discusses the discovery, structure-activity relationships, and molecular mechanisms of P7C3, with a particular emphasis on mitochondrial dynamics and redox homeostasis. The efficacy of P7C3 in preclinical studies was evaluated across Alzheimer's disease (AD), Parkinson's disease (PD), traumatic brain injury (TBI), ischemic stroke, depression, and chemotherapy-induced neuropathy. These neuroprotective effects occur independently of disease-specific aggregates. Challenges hindering clinical application include the on-target safety of NAMPT activation given the concurrent development of NAMPT inhibitors for tumorigenesis, the absence of validated predictive biomarkers, and the failure of prior NAMPT-targeting trials. CONCLUSIONS: P7C3 illustrates how phenotypic screening coupled with target deconvolution can yield therapeutic candidates with potential applications across a broad spectrum of neurological disorders.
Abstract as published, via PubMed.
For healthcare professionals. The summary is generated by AI from the published abstract, and the evidence level is assigned automatically from the study design on the Oxford CEBM hierarchy. Neither is medical advice. Read the full paper before changing practice.